Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis

被引:17
作者
Qu, Mengying [1 ]
Wan, Siyuan [1 ,2 ]
Ren, Bingxuan [1 ]
Wu, Huaiyong [1 ]
Liu, Lixiang [1 ]
Shen, Hongmei [1 ]
机构
[1] Harbin Med Univ, Ctr Endem Dis Control, Chinese Ctr Dis Control & Prevent, Harbin, Heilongjiang, Peoples R China
[2] Qiqihar Med Univ, Dept Prevent Med, Qiqihar, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Papillary thyroid cancer; TSHR gene; Methylation; Meta-analysis; EXPRESSION; MUTATION;
D O I
10.1007/s12020-020-02284-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose To explore the association between the thyroid stimulating hormone receptor (TSHR) gene methylation and human papillary thyroid cancer (PTC), as well as PTC related clinicopathological indicators. Methods We searched PubMed, Embase, Medline, and Web of Science databases through computer for articles published in English on association between methylation of TSHR gene and PTC. Articles published in Chinese were searched in China National Knowledge Infrastructure (CNKI), WanFang, China Biology Medicine (CBM) disc, and WeiPu databases. Database search took place in the 4th week of October. Results Totally 914 samples from 14 case-control studies were included in our meta-analysis. The methylation rate of TSHR gene in PTC group was significantly greater than that in control group (OR = 6.45, 95% CI 3.03, 13.71, P < 0.001). The subgroup analysis results showed the incidence of TSHR gene methylation was higher in autologous controls (OR = 16.39, 95% CI 8.83, 30.42, P < 0.001), Asian races (OR = 8.26, 95% CI 3.54, 19.23, P < 0.001), and Chinese (OR = 11.40, 95% CI 5.56, 23.39, P < 0.001). Hierarchical analysis of PTC related clinicopathological indicators showed that TSHR gene methylation rate are higher in PTC patients over 45 years (OR = 1.65, 95% CI 1.07, 2.55, P < 0.05) and lymph node metastasis (OR = 5.36, 95% CI 1.54, 18.67, P < 0.01). In addition, the occurrence of TSHR gene methylation had also been shown to be related to the clinical stage (OR = 0.23, 95% CI 0.07, 0.70, P < 0.05) and size (OR = 0.19, 95% CI 0.11, 0.32, P < 0.01) of tumors. The result of sensitivity analysis showed the combined results of the studies included in the meta-analysis were fairly stable. Begg's and Egger's tests also suggested that there was no significance publication bias (P > 0.1). Conclusions The rate of TSHR gene methylation is higher in PTC and it may be associated with the pathogenesis of human PTC, suggesting that TSHR gene may be a candidate marker for PTC diagnosis. In addition, the occurrence of TSHR gene methylation in PTC patients is closely related to age, lymph node metastasis, clinical stage, and tumor size, suggesting that TSHR gene may be used as an index to judge the severity of PTC.
引用
收藏
页码:508 / 515
页数:8
相关论文
共 33 条
  • [1] Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations
    Abdullah, Mardiaty Iryani
    Junit, Sarni Mat
    Ng, Khoon Leong
    Jayapalan, Jaime Jacqueline
    Karikalan, Barani
    Hashim, Onn Haji
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (03): : 450 - 460
  • [2] Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer
    Brait, Mariana
    Loyo, Myriam
    Rosenbaum, Eli
    Ostrow, Kimberly L.
    Markova, Alina
    Papagerakis, Silvana
    Zahurak, Marianna
    Goodman, Steven N.
    Zeiger, Martha
    Sidransky, David
    Umbricht, Christopher B.
    Hoque, Mohammad O.
    [J]. EPIGENETICS, 2012, 7 (07) : 710 - 719
  • [3] DAI Y, 2012, J CAP MED U, V33, P83, DOI DOI 10.3969/J.ISSN.10067795.2012.03.016
  • [4] GAO M, 2018, EXPRESSION SIGNIFICA
  • [5] HUANG Y, 2017, JIANGXI MED J, V52
  • [6] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20107, 10.3322/caac.20115, 10.3322/caac.21492]
  • [7] The epigenomics of cancer
    Jones, Peter A.
    Baylin, Stephen B.
    [J]. CELL, 2007, 128 (04) : 683 - 692
  • [8] Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material
    Kartal, Kinyas
    Onder, Sevgen
    Kosemehmetoglu, Kemal
    Kilickap, Sadettin
    Tezel, Yesim Gaye
    Kaynaroglu, Volkan
    [J]. BMC CANCER, 2015, 15
  • [9] Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status
    Khan, Mosin S.
    Pandith, Arshad A.
    Masoodi, Shariq R.
    Wani, Khursheed A.
    Ul Hussain, Mahboob
    Mudassar, Syed
    [J]. ENDOCRINE, 2014, 47 (02) : 449 - 455
  • [10] Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer
    Khatami, Fatemeh
    Larijani, Bagher
    Heshmat, Ramin
    Keshtkar, Abbasali
    Mohammadamoli, Mahsa
    Teimoori-Toolabi, Ladan
    Nasiri, Shirzad
    Tavangar, Seyed Mohammad
    [J]. PLOS ONE, 2017, 12 (09):